FDA review and mutant-cohort data are the key catalysts, with cash expected to fund operations through 2027. [7][10][43]
| Quarter | Q4 FY25 |
|---|---|
| Call date | 2026-03-26 |
| Length | 47 minutes |
| EPS | $-0.97 |
| EPS consensus | $-1.06 |
| Revenue | $3.6M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q2 FY25
All CELC earnings · Back to CELC overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.